| Morris, David |
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent |
|
|
| Terminated | 3 | 105 | US | VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga | Veru Inc. | Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer | 05/23 | 05/23 | | |
CLARIFY, NCT06056830: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy |
|
|
| Recruiting | 3 | 383 | US, RoW | 64Cu-SAR-bisPSMA | Clarity Pharmaceuticals Ltd | Prostate Cancer, Prostatic Neoplasms | 02/25 | 02/25 | | |
NCT05903131: A Behavioral Intervention to Promote Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia |
|
|
| Recruiting | 2 | 96 | US | Telemedicine behavioral weight intervention, Progestin, Enhanced usual care, Levonorgestrel-releasing IUD. | Washington University School of Medicine, National Cancer Institute (NCI) | Endometrial Hyperplasia, Grade 1 Endometrial Cancer | 10/28 | 10/29 | | |
NCT05829460: Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia |
|
|
| Not yet recruiting | 2 | 96 | US | Semaglutide, Placebo, LNG-IUD (Progestin), Telemedicine behavioral weight program | Washington University School of Medicine, Novo Nordisk A/S | Endometrial Hyperplasia | 12/29 | 12/31 | | |
| Terminated | 1/2 | 102 | Europe, US | Tazemetostat, EPZ-6438, E7438, IPN60200, Abiraterone/prednisone, Zytiga, Enzalutamide, Xtandi | Epizyme, Inc. | Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer | 11/24 | 11/24 | | |
|
|
NCT05497934: The Effects of Glycerol as an Optical Clearing Agent for Visualization of the Middle Ear |
|
|
| Withdrawn | 1 | 50 | NA | Glycerol, Glycerin(e) | Nova Scotia Health Authority, Dalhousie University | Tympanosclerosis, Thickened Ears, Healthy, Surgery | 10/23 | 03/24 | | |
| Recruiting | 1 | 174 | US | PRL-02 injection, prednisone, dexamethasone, enzalutamide | Astellas Pharma Global Development, Inc. | Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer | 08/25 | 05/29 | | |
NCT05492513: Constraint-Induced Movement Therapy for Adults Post-Stroke With Mild Upper Extremity Impairment |
|
|
| Recruiting | N/A | 12 | US | Grade 1 CI Therapy +Sensory Components | University of Alabama at Birmingham | CVA (Cerebrovascular Accident), Stroke, Upper Extremity Paresis | 11/25 | 03/26 | | |
NCT05515237: Constraint-Induced Movement Therapy Plus Sensory Components After Stroke |
|
|
| Recruiting | N/A | 15 | US | Grade 2-5 CI Therapy + Sensory Components | University of Alabama at Birmingham | CVA (Cerebrovascular Accident), Stroke, Upper Extremity Paresis | 03/26 | 06/26 | | |
NCT06310278: Ossiview Normative Mobility Data Collection Protocol |
|
|
| Recruiting | N/A | 120 | Canada | Ossicular mobility measurement | Audioptics Medical Incorporated | Conductive Hearing Loss, Middle Ear | 10/24 | 10/24 | | |
CISTO, NCT03933826: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer |
|
|
| Active, not recruiting | N/A | 572 | US | | University of Washington, Patient-Centered Outcomes Research Institute | Bladder Cancer, Cancer of the Bladder, Recurrent, Non-muscle Invasive Bladder Cancer | 12/24 | 03/25 | | |
| Warlick, Christopher |
HEAT, NCT06014255: Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer |
|
|
| Recruiting | 2 | 219 | US | Enoblituzumab, MGA271, Standard of Care | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, MacroGenics | Prostate Cancer | 03/29 | 03/29 | | |
NCT03988309: STRATA: Safe Testing of Risk for AsymptomaTic MicrohematuriA |
|
|
| Active, not recruiting | N/A | 554 | Canada, US | Cxbladder | Pacific Edge Limited | Hematuria, Urothelial Carcinoma | 12/24 | 12/24 | | |
| Active, not recruiting | N/A | 400 | US | Vanquish System | Francis Medical Inc. | Prostate Cancer | 04/27 | 04/29 | | |
| Kernen, Kenneth |
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent |
|
|
| Terminated | 3 | 105 | US | VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga | Veru Inc. | Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer | 05/23 | 05/23 | | |
| Active, not recruiting | N/A | 400 | US | Vanquish System | Francis Medical Inc. | Prostate Cancer | 04/27 | 04/29 | | |
| Henry, Gerard |
NCT05287438: Next Generation Sequencing Versus Traditional Cultures for Clinically Infected Penile Implants: Impact of Culture Identification on Outcomes |
|
|
| Recruiting | N/A | 40 | US | Next-Generation DNA Sequencing, NGS, Standard Culture | MicroGenDX | Penile Implantation, Infections | 10/23 | 10/24 | | |
NCT06217328: RESTORE: An RCT to Evaluate the Efficacy of the Revi System |
|
|
| Recruiting | N/A | 150 | US | Revi System Treatment, Revi System - Delayed Activation | BlueWind Medical | Urinary Urge Incontinence | 05/26 | 05/27 | | |
NCT06511141: Sacral Neuromodulation for Male Overactive Bladder (MOAB) |
|
|
| Recruiting | N/A | 120 | US | Axonics SNM System | Axonics, Inc. | Overactive Bladder, Urinary Urgency Incontinence, Benign Prostatic Hyperplasia, Prostate Cancer, Prostatectomy | 12/26 | 03/27 | | |
| Active, not recruiting | N/A | 400 | US | Vanquish System | Francis Medical Inc. | Prostate Cancer | 04/27 | 04/29 | | |
| Kella, Naveen |
CLARIFY, NCT06056830: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy |
|
|
| Recruiting | 3 | 383 | US, RoW | 64Cu-SAR-bisPSMA | Clarity Pharmaceuticals Ltd | Prostate Cancer, Prostatic Neoplasms | 02/25 | 02/25 | | |
CAPTAIN, NCT05027477: A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer |
|
|
| Recruiting | N/A | 201 | Europe, Canada, US | Radical Prostatectomy, TULSA Procedure, TULSA-PRO | Profound Medical Inc. | Prostate Cancer, Prostate Adenocarcinoma | 12/24 | 12/34 | | |
NCT06217328: RESTORE: An RCT to Evaluate the Efficacy of the Revi System |
|
|
| Recruiting | N/A | 150 | US | Revi System Treatment, Revi System - Delayed Activation | BlueWind Medical | Urinary Urge Incontinence | 05/26 | 05/27 | | |
NCT04757116: Post-Market Study to Assess iTind Safety in Comparison to UroLift |
|
|
| Recruiting | N/A | 206 | Europe, US | iTind, UroLift | Olympus Corporation of the Americas | Benign Prostatic Hyperplasia (BPH) | 12/25 | 12/30 | | |
| Recruiting | N/A | 1000 | US | TULSA Procedure | Profound Medical Inc. | Prostate Cancer, Prostate Adenocarcinoma, Benign Prostatic Hyperplasia | 10/26 | 10/61 | | |
| Active, not recruiting | N/A | 400 | US | Vanquish System | Francis Medical Inc. | Prostate Cancer | 04/27 | 04/29 | | |
| Shore, Neal D |
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent |
|
|
| Terminated | 3 | 105 | US | VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga | Veru Inc. | Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer | 05/23 | 05/23 | | |
BOND3, NCT04452591: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin |
|
|
| Recruiting | 3 | 190 | Japan, US, RoW | Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside, DDM | CG Oncology, Inc. | Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer | 12/27 | 12/29 | | |
| Recruiting | 3 | 100 | Europe, US, RoW | padeliporfin VTP, WST11 | Steba Biotech S.A., PrimeVigilance, ICON plc | Transitional Cell Cancer of Renal Pelvis and Ureter | 12/24 | 01/29 | | |
CLARIFY, NCT06056830: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy |
|
|
| Recruiting | 3 | 383 | US, RoW | 64Cu-SAR-bisPSMA | Clarity Pharmaceuticals Ltd | Prostate Cancer, Prostatic Neoplasms | 02/25 | 02/25 | | |
PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC |
|
|
| Active, not recruiting | 3 | 1145 | Europe, Canada, Japan, US, RoW | 177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT | Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc. | Prostatic Neoplasms | 07/25 | 02/26 | | |
|
NCT04691804 / 2020-006063-28: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer |
|
|
| Active, not recruiting | 3 | 496 | Europe, US, RoW | Fuzuloparib , Abiraterone acetate and Prednisone, SHR3162, Fuzuloparib Placebo， Abiraterone acetate and Prednisone | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 12/26 | 12/26 | | |
TURBT, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following |
|
|
| Recruiting | 3 | 364 | Canada, US | Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM | CG Oncology, Inc. | Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma | 01/28 | 01/30 | | |
PSMA-DC, NCT05939414: An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. |
|
|
| Recruiting | 3 | 450 | Europe, Canada, Japan, US, RoW | AAA617, (177Lu) vipivotide tetraxetan | Novartis Pharmaceuticals | Oligometastatic Prostate Cancer (OMPC) | 12/27 | 07/30 | | |
SABRE, NCT05407311: 64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer |
|
|
| Completed | 2 | 53 | US | 64Cu-SAR-BBN | Clarity Pharmaceuticals Ltd | Biochemical Recurrence of Malignant Neoplasm of Prostate | 05/24 | 05/24 | | |
NCT03914794: A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors |
|
|
| Recruiting | 2 | 43 | US | Pemigatinib, INCB054828, FGFR inhibitor INCB054828 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Incyte Corporation | Bladder Cancer, NMIBC, Non-Muscle Invasive Bladder Cancer, Urothelial Carcinoma Recurrent | 05/25 | 05/26 | | |
|
NCT06567743: Brief Title: Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC |
|
|
| Recruiting | 2 | 50 | US | Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM | CG Oncology, Inc. | High-Risk Non-Muscle-Invasive Bladder Cancer | 03/27 | 12/27 | | |
NCT06636682: FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer |
|
|
| Recruiting | 2 | 100 | US | FK-PC101, Standard of Care (SOC) | Cellvax Therapeutics Inc | Prostate Cancer (Adenocarcinoma), Prostate CA, Prostate Cancers, Prostate Cancer (Post Prostatectomy), Prostate Cancer, Prostate Cancer Patients Undergoing Radical Prostatectomy, High-risk Prostate Cancer | 02/27 | 05/27 | | |
NCT03945162: Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients |
|
|
| Recruiting | 2 | 125 | Canada, US | Ruvidar® (TLD-1433) Bladder infusion and PDT | Theralase® Technologies Inc., University Health Network, Toronto, Pharma eMarket | Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG | 06/25 | 12/25 | | |
Tamarack, NCT05551117: A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors |
|
|
| Active, not recruiting | 2 | 192 | Europe, US, RoW | vobramitamab duocarmazine 2.0 mg (Arm A), MGC018, vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine, Abiraterone, Enzalutamide | MacroGenics | Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Anal Cancer, Anal Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Malignant Melanoma, Melanoma, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Small-cell Lung Cancer, Small Cell Carcinoma | 07/24 | 02/25 | | |
|
PSMACare, NCT05849298: A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC |
|
|
| Recruiting | 2 | 120 | Europe, Canada, US, RoW | AAA617, Lutetium [177Lu] vipivotide tetraxetan, 177Lu-PSMA-617, AAA517, 68Ga-PSMA-11, Piflufolastat F 18, ARPI, ADT, Best supportive care | Novartis Pharmaceuticals | Prostatic Neoplasm | 10/27 | 12/28 | | |
| Terminated | 1b/2 | 24 | US | VERU-100 | Veru Inc. | Advanced Prostate Adenocarcinoma | 01/23 | 01/23 | | |
COBRA, NCT05249127: 64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer |
|
|
| Completed | 1/2 | 52 | US | 64Cu-SAR-bisPSMA | Clarity Pharmaceuticals Ltd | Biochemical Recurrence of Malignant Neoplasm of Prostate | 08/23 | 08/23 | | |
LEGEND study, NCT04752722: LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve |
|
|
| Recruiting | 1/2 | 222 | Canada, US | EG-70 (phase 1), Phase 1, EG-70 (phase 2), Phase 2 | enGene, Inc. | Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ | 06/25 | 05/27 | | |
NCT05617040: Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer |
|
|
| Active, not recruiting | 1/2 | 144 | US | ChAdOx1-PCAQ, MVA-PCAQ | Barinthus Biotherapeutics | Prostate Cancer | 08/26 | 04/27 | | |
| Recruiting | 1 | 174 | US | PRL-02 injection, prednisone, dexamethasone, enzalutamide | Astellas Pharma Global Development, Inc. | Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer | 08/25 | 05/29 | | |
| Recruiting | 1 | 24 | US | ZH9 | Prokarium Ltd | NMIBC, High Risk NMIBC, Non Muscle Invasive Bladder Cancer | 06/25 | 07/27 | | |
| Recruiting | 1 | 180 | Europe, Canada, Japan, US, RoW | LOXO-435, LY3866288, Pembrolizumab, KEYTRUDA® | Eli Lilly and Company, Merck Sharp & Dohme LLC | Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms | 06/25 | 06/25 | | |
NCT05508568: A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer |
|
|
| Recruiting | N/A | 650 | US | ADXBLADDER | Arquer Diagnostics Ltd | Bladder Cancer | 01/23 | 04/23 | | |
| Active, not recruiting | N/A | 279 | US | Zenflow Spring System, Sham Procedure, Foley Catheter | Zenflow, Inc. | BPH (Benign Prostatic Hyperplasia), Lower Urinary Tract Symptoms (LUTS) | 06/24 | 06/26 | | |
| Completed | N/A | 804 | Europe, Canada, US | Micro-US Targeted Biopsy, MRI Targeted Biopsy | Sunnybrook Health Sciences Centre, Exact Imaging | Prostate Cancer | 09/24 | 11/24 | | |
CISTO, NCT03933826: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer |
|
|
| Active, not recruiting | N/A | 572 | US | | University of Washington, Patient-Centered Outcomes Research Institute | Bladder Cancer, Cancer of the Bladder, Recurrent, Non-muscle Invasive Bladder Cancer | 12/24 | 03/25 | | |
NCT03988309: STRATA: Safe Testing of Risk for AsymptomaTic MicrohematuriA |
|
|
| Active, not recruiting | N/A | 554 | Canada, US | Cxbladder | Pacific Edge Limited | Hematuria, Urothelial Carcinoma | 12/24 | 12/24 | | |
| Active, not recruiting | N/A | 400 | US | Vanquish System | Francis Medical Inc. | Prostate Cancer | 04/27 | 04/29 | | |
| Shahi, Seema |
NCT06217328: RESTORE: An RCT to Evaluate the Efficacy of the Revi System |
|
|
| Recruiting | N/A | 150 | US | Revi System Treatment, Revi System - Delayed Activation | BlueWind Medical | Urinary Urge Incontinence | 05/26 | 05/27 | | |
| Recruiting | N/A | 180 | US | | Laborie Medical Technologies Inc. | Urinary Incontinence, Urinary Obstruction, Urinary Bladder, Overactive, Urinary Bladder, Neurogenic, Urinary Incontinence, Urge | 11/25 | 12/25 | | |
| Capilla, Francisco |
NCT05519293: Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation |
|
|
| Recruiting | 1/2 | 76 | US | H002 | RedCloud Bio, Parexel | Non-small Cell Lung Cancer | 02/25 | 02/25 | | |
NCT03715933: Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas |
|
|
| Recruiting | 1 | 321 | Europe, US | INBRX-109, Carboplatin, Cisplatin, Pemetrexed, 5-fluorouracil, Irinotecan, Temozolomide | Inhibrx Biosciences, Inc | Colorectal Adenocarcinoma, Ewing Sarcoma | 06/26 | 12/26 | | |
NCT06075810: A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer |
|
|
| Recruiting | 1 | 48 | US | MBQ-167, Rac and Cdc42 inhibitor, Rac inhibitor, Cdc42 inhibitor, PAK inhibitor, Rac/Cdc42 inhibitor | MBQ Pharma, Congressionally Directed Medical Research Programs | Breast Cancer, Breast Neoplasm, Breast Cancer Stage IV | 10/25 | 10/25 | | |
NCT06667141: Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors |
|
|
| Recruiting | 1 | 90 | US | ACR-2316 | Acrivon Therapeutics | Specific Advanced Solid Tumors | 08/26 | 12/26 | | |
CAPTAIN, NCT05027477: A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer |
|
|
| Recruiting | N/A | 201 | Europe, Canada, US | Radical Prostatectomy, TULSA Procedure, TULSA-PRO | Profound Medical Inc. | Prostate Cancer, Prostate Adenocarcinoma | 12/24 | 12/34 | | |
| Krane, Louis |
NCT04757116: Post-Market Study to Assess iTind Safety in Comparison to UroLift |
|
|
| Recruiting | N/A | 206 | Europe, US | iTind, UroLift | Olympus Corporation of the Americas | Benign Prostatic Hyperplasia (BPH) | 12/25 | 12/30 | | |
| Giusto, Laura |
| Recruiting | N/A | 200 | Europe, US | RENOVA iStim™ System | BlueWind Medical | Treatment of Patients Suffering From Overactive Bladder (OAB) | 10/22 | 01/25 | | |
| Recruiting | N/A | 390 | US | Active treatment, Sham | Viveve Inc. | Urinary Incontinence, Stress | 12/22 | 12/22 | | |
| Active, not recruiting | N/A | 188 | US | Medtronic Implantable Tibial Neuromodulation (TNM) System | MedtronicNeuro | Overactive Bladder | 10/23 | 04/25 | | |
NCT06217328: RESTORE: An RCT to Evaluate the Efficacy of the Revi System |
|
|
| Recruiting | N/A | 150 | US | Revi System Treatment, Revi System - Delayed Activation | BlueWind Medical | Urinary Urge Incontinence | 05/26 | 05/27 | | |
| Recruiting | N/A | 180 | US | | Laborie Medical Technologies Inc. | Urinary Incontinence, Urinary Obstruction, Urinary Bladder, Overactive, Urinary Bladder, Neurogenic, Urinary Incontinence, Urge | 11/25 | 12/25 | | |
| Talaty, Pooja |
| Recruiting | 2 | 70 | US | Adalimumab, Placebo will be administered subcutaneously every 2 weeks, for a total of 6 injections. | NorthShore University HealthSystem, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Benign Prostatic Hyperplasia (BPH) | 04/28 | 06/28 | | |
| Active, not recruiting | N/A | 121 | US | Irreversible Electroporation, The NanoKnife System | Angiodynamics, Inc. | Prostate Cancer | 07/24 | 07/24 | | |
GenBx, NCT05295407: Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy |
|
|
| Recruiting | N/A | 1000 | US | Genetic Assessment | NorthShore University HealthSystem, Northwestern University, Johns Hopkins University, GoPath Diagnostics | Prostate Cancer | 12/24 | 12/25 | | |
NCT04757116: Post-Market Study to Assess iTind Safety in Comparison to UroLift |
|
|
| Recruiting | N/A | 206 | Europe, US | iTind, UroLift | Olympus Corporation of the Americas | Benign Prostatic Hyperplasia (BPH) | 12/25 | 12/30 | | |
| Not yet recruiting | N/A | 280 | Europe, Canada, US, RoW | Aquablation Therapy, Radical Prostatectomy | PROCEPT BioRobotics | Localized Prostate Cancer | 07/27 | 01/37 | | |
NCT06054867: PRCT002 PRostate Cancer Treatment With the AQUABEAM Robotic System |
|
|
| Active, not recruiting | N/A | 22 | US | Robotic Waterjet Treatment, Aquablation therapy | PROCEPT BioRobotics | Localized Prostate Cancer | 04/25 | 04/25 | | |
NCT06051942: PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs |
|
|
| Recruiting | N/A | 125 | US, RoW | Robotic Waterjet Treatment, Aquablation therapy | PROCEPT BioRobotics | Benign Prostatic Hyperplasia, Localized Prostate Cancer | 08/25 | 05/26 | | |
NCT05898932: Enhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia Using Patient-Reported Outcomes |
|
|
| Recruiting | N/A | 300 | US | Medical Management, Surgical Management | Northwestern University, NorthShore University HealthSystem, University of Chicago | Benign Prostatic Hyperplasia | 08/26 | 08/26 | | |
NCT05608694: MRI Screening in Men at High Risk of Developing Prostate Cancer |
|
|
| Recruiting | N/A | 250 | US | Prostate MRI | University of Chicago | Prostate Cancer Screening | 03/37 | 03/39 | | |
| Parker, Alexander S |
CLARIFY, NCT06056830: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy |
|
|
| Recruiting | 3 | 383 | US, RoW | 64Cu-SAR-bisPSMA | Clarity Pharmaceuticals Ltd | Prostate Cancer, Prostatic Neoplasms | 02/25 | 02/25 | | |
| Recruiting | N/A | 750 | US | Disease Risk Assessment | Duke University, National Human Genome Research Institute (NHGRI) | Cardiovascular Diseases, Cancer, Liver Diseases, Hyperthermia | 06/25 | 06/25 | | |
| Not yet recruiting | N/A | 2400 | NA | AGILITY (Access to Genetic Information Leveraging Innovative TechnologY), Chatbot | RTI International, University of Florida | Genetic Testing | 09/24 | 09/25 | | |
| Arnold, Jenny |
CAPTAIN, NCT05027477: A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer |
|
|
| Recruiting | N/A | 201 | Europe, Canada, US | Radical Prostatectomy, TULSA Procedure, TULSA-PRO | Profound Medical Inc. | Prostate Cancer, Prostate Adenocarcinoma | 12/24 | 12/34 | | |
| Hatchet, Jayla |
NCT04757116: Post-Market Study to Assess iTind Safety in Comparison to UroLift |
|
|
| Recruiting | N/A | 206 | Europe, US | iTind, UroLift | Olympus Corporation of the Americas | Benign Prostatic Hyperplasia (BPH) | 12/25 | 12/30 | | |
| Hatcher, Jayla |
| Active, not recruiting | N/A | 150 | US | Holter monitoring in patients who have been successfully implanted with an Abbott Assert-IQ ICM device | Abbott Medical Devices | Atrial Fibrillation Paroxysmal, Atrial Fibrillation, Persistent, Cardiac Arrhythmia, Ablation | 12/24 | 12/25 | | |
| Recruiting | N/A | 2650 | Europe, Canada, Japan, US, RoW | Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder), Amplatzer Amulet LAA Occluder, Non-Vitamin K Oral Antagonists, NOAC | Abbott Medical Devices | Atrial Fibrillation, Stroke, Bleeding | 08/27 | 08/30 | | |
| Active, not recruiting | N/A | 400 | US | Vanquish System | Francis Medical Inc. | Prostate Cancer | 04/27 | 04/29 | | |
| Twedt, Maressa |
NCT06190197: Prophylactic Antibiotics in Cystectomy With Diversion |
|
|
| Recruiting | 1 | 120 | US | Prophylactic antibiotics postoperatively. | University of Minnesota | Muscle-Invasive Bladder Carcinoma, Radical Cystectomy, Ileal Conduit, Neobladder Diversion | 10/26 | 10/26 | | |
| Active, not recruiting | N/A | 400 | US | Vanquish System | Francis Medical Inc. | Prostate Cancer | 04/27 | 04/29 | | |
| Recruiting | N/A | 4400 | US | Hexaminolevulinate hydrochloride (HCL), Cysview®, Hexvix®, Karl Storz D-Light C Photodynamic Diagnostic (PDD) system | Photocure, Catalyst Pharmaceutical Research | Bladder Cancer | 12/28 | 12/28 | | |
| Sarwan, Victoria |
CAPTAIN, NCT05027477: A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer |
|
|
| Recruiting | N/A | 201 | Europe, Canada, US | Radical Prostatectomy, TULSA Procedure, TULSA-PRO | Profound Medical Inc. | Prostate Cancer, Prostate Adenocarcinoma | 12/24 | 12/34 | | |
NCT06217328: RESTORE: An RCT to Evaluate the Efficacy of the Revi System |
|
|
| Recruiting | N/A | 150 | US | Revi System Treatment, Revi System - Delayed Activation | BlueWind Medical | Urinary Urge Incontinence | 05/26 | 05/27 | | |
NCT04757116: Post-Market Study to Assess iTind Safety in Comparison to UroLift |
|
|
| Recruiting | N/A | 206 | Europe, US | iTind, UroLift | Olympus Corporation of the Americas | Benign Prostatic Hyperplasia (BPH) | 12/25 | 12/30 | | |
| Recruiting | N/A | 1000 | US | TULSA Procedure | Profound Medical Inc. | Prostate Cancer, Prostate Adenocarcinoma, Benign Prostatic Hyperplasia | 10/26 | 10/61 | | |
| Active, not recruiting | N/A | 400 | US | Vanquish System | Francis Medical Inc. | Prostate Cancer | 04/27 | 04/29 | | |
| Carlson, Holly |
NCT05806996: A Study of Magnesium and Bladder Spasms Following Ambulatory Urologic Procedures |
|
|
| Recruiting | 2 | 120 | US | Magnesium, Placebo | Mayo Clinic | Bladder Spasms | 06/25 | 12/25 | | |
| Active, not recruiting | N/A | 400 | US | Vanquish System | Francis Medical Inc. | Prostate Cancer | 04/27 | 04/29 | | |
| Alarcon, Juan Antonio |
CAPTAIN, NCT05027477: A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer |
|
|
| Recruiting | N/A | 201 | Europe, Canada, US | Radical Prostatectomy, TULSA Procedure, TULSA-PRO | Profound Medical Inc. | Prostate Cancer, Prostate Adenocarcinoma | 12/24 | 12/34 | | |
| Chandrasoma, Shahin |
CAPTAIN, NCT05027477: A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer |
|
|
| Recruiting | N/A | 201 | Europe, Canada, US | Radical Prostatectomy, TULSA Procedure, TULSA-PRO | Profound Medical Inc. | Prostate Cancer, Prostate Adenocarcinoma | 12/24 | 12/34 | | |
NCT06217328: RESTORE: An RCT to Evaluate the Efficacy of the Revi System |
|
|
| Recruiting | N/A | 150 | US | Revi System Treatment, Revi System - Delayed Activation | BlueWind Medical | Urinary Urge Incontinence | 05/26 | 05/27 | | |
| Amarasekera, Channa |
NCT04757116: Post-Market Study to Assess iTind Safety in Comparison to UroLift |
|
|
| Recruiting | N/A | 206 | Europe, US | iTind, UroLift | Olympus Corporation of the Americas | Benign Prostatic Hyperplasia (BPH) | 12/25 | 12/30 | | |
| Grewal, Shaun GS |
CLARIFY, NCT06056830: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy |
|
|
| Recruiting | 3 | 383 | US, RoW | 64Cu-SAR-bisPSMA | Clarity Pharmaceuticals Ltd | Prostate Cancer, Prostatic Neoplasms | 02/25 | 02/25 | | |
| Talavera, Kristine |
TURBT, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following |
|
|
| Recruiting | 3 | 364 | Canada, US | Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM | CG Oncology, Inc. | Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma | 01/28 | 01/30 | | |
